AUROBINDO PHARMA
|
|
BOM : 524804     NSE : AUROPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Mar 18,2024 |
Price(EOD): ₹ 1,017.45
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 59,612.40 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | -2.6% | -1.6% | 122.3% |
SUN PHARMACEUTICAL INDUSTRIES | -0.8% | 4% | 61.6% |
DIVIS LABORATORIES | -2.1% | -6% | 26.4% |
CIPLA | 1.5% | 3.3% | 70.6% |
DR REDDYS LABORATORIES | 0.7% | 0.4% | 44.6% |
TORRENT PHARMACEUTICALS | -4% | -2.8% | 70.3% |
ABBOTT INDIA | 6% | -3% | 39.7% |
ZYDUS LIFESCIENCES | 0.3% | 11.1% | 109.1% |
ALKEM LABORATORIES | -1.5% | -8.6% | 63.1% |
FUNDAMENTAL ANALYSIS OF AUROBINDO PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AUROBINDO PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
21.46
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 2,777.89 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] 2.22
P/B Calculated based on Book Value of Rs 26,839.80 Cr
[Latest Year - Mar2023 - Consolidated Results ] 2.14
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 27,894.70 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-6% -22% 0% |
SHARE PRICE MOMENTUM OF AUROBINDO PHARMA
AUROBINDO PHARMA vs SENSEX
DEBT OF AUROBINDO PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.23 0.11 0.25 0.2 |
0.18 0.1 0.23 0.17 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF AUROBINDO PHARMA
Pledged Promoter Shares |
18.9 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF AUROBINDO PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
1.83% 16.59% 17.7% 25.5% |
14.74% 67.78% 85.84% 91.73% |
QtrlyTrend |
8 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
AUROBINDO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE LARGE MIDCAP | -1.9% | -0.1% | 35.5% |
S&P BSE 200 | -1.9% | -0.1% | 35.3% |
S&P BSE 250 LARGEMIDCAP | -2% | -0.4% | 35.3% |
S&P BSE HEALTHCARE | -2.1% | -2.4% | 59.2% |
S&P BSE 500 | -2.2% | -0.9% | 36.5% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY PHARMA | -2% | 1.3% | 62.2% |
NIFTY 200 | -2% | -0.3% | 35.5% |
NIFTY HEALTHCARE | -2.1% | -1% | 59.4% |
NIFTY 500 | -2.2% | -1% | 37.3% |
NIFTY LARGE MIDCAP 250 | -2.7% | -1.8% | 41.9% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA
Is AUROBINDO PHARMA good for long term investment?
As on Mar 18,2024, the Fundamentals of AUROBINDO PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AUROBINDO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AUROBINDO PHARMA UnderValued or OverValued?
As on Mar 18,2024, AUROBINDO PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of AUROBINDO PHARMA ?
As on Mar 18,2024, the Intrinsic Value of AUROBINDO PHARMA is Rs. 1,085.78 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,085.78
Fair Value [Median EV / Sales Model] : Rs. 1,303.63
Fair Value [Median Price / Sales Model] : Rs. 1,016.96
Estimated Median Fair Value of AUROBINDO PHARMA : Rs. 1,085.78
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.